Clinical Trials & Treatment Updates
Find out more about clinical trials and the companies that instigate by following the links below;
Cyclo Therapeutics to present clinical and drug development program for Trappsol® Cyclo™, at WORLDSymposium 2021
January 26, 2021
a clinical stage biotechnology company developing a cyclodextrin platform for the treatment of Neurodegenerative Diseases, including their lead candidate (Trappsol® Cyclo™) in the treatment of Niemann-Pick Disease Type C (NPC)
IntraBio New Drug Application Approved by the FDA for the Treatment of NPC
February 16, 2019
This approval allows IntraBio to begin with the trial at U.S. clinical sites. In addition to the U.S. centers, IntraBio intends to commence the study in European countries, including the United Kingdom, Germany, Slovakia, and Spain
Orphazyme reports positive results from full data set of Phase II/III arimoclomol trial in Niemann-Pick disease Type C (NPC)
January 30, 2019
Primary endpoint shows 74% reduction in disease progression after 12 months compared to placebo control
CTD Announces Presentation at Upcoming Conference on Lysosomal Storage Diseases
January 11, 2019
CTD Holdings: Annual conference offers opportunities for academic researchers and industry representatives to exchange information on novel therapeutic interventions...